Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection

Yu-Jen Chen a, Shou-Cheng Wu a, Chung-Yung Chen b, Shey-Cherng Tzou a, Tian-Lu Cheng c, Ying-Fang Huang a, Shyng-Shiou Yuan d,*, Yun-Ming Wang a,*

a Department of Biological Science and Technology, National Chiao Tung University, 75 Bo-Ai Street, Hsinchu 300, Taiwan
b Department of Bioscience Technology, Chung Yuan Christian University, Chungli 320, Taiwan
c Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung 807, Taiwan
d Translational Research Center, Cancer Center, and Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan

ARTICLE INFO

Article history:
Received 6 September 2013
Accepted 25 September 2013
Available online 10 October 2013
Keywords:
Legumain
MRI
Optical imaging
Contrast agent

ABSTRACT

Recent studies suggest that intratumoral legumain promotes tumorigenesis. To monitor legumain activity in tumors, we developed a new MRI contrast agent ([Gd-NBCB-TTDA-Leg(L)]) and a NIR fluorescence probe (CyTE777-Leg(L)-CyTE807). The MRI contrast agent was prepared by introduction of cyclobutyl and benzyl group residues to TTDA (3,6,10-tri(carboxymethyl)-3,6,10-triaza-dodecanedioic acid), followed by the attachment of a legumain-specific substrate peptide (Leg(L)). The NIR fluorescence probe was designed by conjugating two NIR fluorochromes (CyTE777 and CyTE807) with Leg(L). Peptide cleavage of the MRI contrast agent by legumain increases its hydrophobicity and promotes rotational correlation time (τR). Peptide cleavage of the NIR probes by the legumain relieves the self quench of the probe. Peptide cleavage of the MRI contrast agent and the NIR fluorescence probe by legumain were confirmed by T1 relaxometric studies and by fluorescence studies, respectively. In vivo MR images showed that [Gd-NBCB-TTDA-Leg(L)] attained 55.3 fold (254.2% versus 4.6%, at 2.0 h post-injection) higher imaging enhancement, as compared with control contrast agent bearing a noncleavable peptide ([Gd-NBCB-TTDA-Leg(D)]) in the CT-26 (legumain+) tumors. Similarly, optical imaging probe CyTE777-Leg(L)-CyTE807 attained 15.2 fold (3.34 × 10^6 photons/min versus 0.22 × 10^6 photons/min, at 24.0 h post-injection) higher imaging enhancement in the CT-26 (legumain+) tumors, compared to a NIR control probe (CyTE777-Leg(D)-CyTE807). These data indicate that the [Gd-NBCB-TTDA-Leg(L)] and the CyTE777-Leg(L)-CyTE807 probes may be promising tools to image the legumain-expressing cancers for diagnoses and targeted treatments.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Magnetic resonance imaging (MRI) is one of the most important tools for cancer diagnosis, and its imaging effect depends upon the combination of MRI contrast agents and the density of water molecules in the body. Advances in MRI have extended the application of this technology from clinical diagnosis to routine cellular imaging [1–3]. Hence, many interdisciplinary researchers have been interested in developing more efficient MRI contrast agents for targeting MR imaging.

Many studies have reported the use of lactoferrin [4], folic acid [5–7], peptide, [8,9] nucleic acid [10], and monoclonal antibodies [11,12] as targeting components of MRI contrast agents. Receptor-mediated endocytosis [13] of these conjugated MRI contrast agents provides an efficient and specific tumor targeting and imaging. On the other hand, optical imaging techniques have been established as a powerful tool for in vitro and in vivo molecular imaging for its superior sensitivity and selectivity [14,15]. In this settings, near-infrared (NIR) fluorochromes are more widely used than fluorochromes with visible spectra since the excitation/emission of NIR (650–900 nm) can penetrate deep tissues without being absorbed by the blood [16,17]. Use of NIR optical imaging has become increasingly attractive to biological scientists due to low
auto-fluorescence, low phototoxicity and deep tissue penetration [18–20]. Proteases participate in tumor formation, angiogenesis, local invasion, and metastatic spread [21–23]. Therefore, proteases may be promising targets for developments of anticancer drugs that act preferentially at cancer sites. In line with this notion, several protease inhibitors, such as the MMP inhibitors marimastat [24], AG3340 [25], S-3304 [26], and BAY 12-9566, [27] have entered phase I, II, and III clinical trials for cancer therapy for colon cancers.

Many studies have clearly revealed the correlation between protease expression and poor prognosis in patients with cancer, [28] indicating that proteases may also be used as markers to predict tumor recurrence and prognostic survival. Thus, tumor-associated proteases seem attractive as both therapeutic targets and prognosis markers. Therefore, the technology to image protease activity in vivo would provide a valuable tool to design personalized, protease activity-based prodrug therapies and to monitor tumor recurrences and patient prognoses. Based on these recent developments, we chose legumain (Leg) as a target in this study. Legumain or asparaginly endopeptidase (AEP) is a lysosomal cysteine protease with a high cleavage specificity after an asparagine residue of substrate proteins [29,30]. Legumain expression and activity are linked to a number of pathological conditions including cancer, atherosclerosis, and inflammation, yet its biological role in these pathologies is not well-understood. It is over-expressed in a majority of human solid tumors such as carcinomas of the breast, colon, and prostate. Knock-down of legumain in mouse cancer models results in marked decrease in tumor growth and metastasis [29]. Several macromolecular substrates have been identified for legumain including MMP-2, [31] cathepsins H, B, L, [32] thymosin [33], and fibronectin [34]. Highly potent and selective inhibitors for legumain would not only be valuable for functional studies of legumain in these conditions, but also useful for therapies as well. In addition, development of imaging probes capable of detecting legumain activity is likely to aid in tumor diagnosis and treatments.

In this study, we designed and synthesized a new MRI contrast agent ([Gd-NBCB-TTDA-Leg(L)]) and a NIR fluorescent probe (CyTE777-Leg(L)-CyTE807) for in vitro and in vivo detection of legumain activity. A cyclobutyl and a benzyl group residues were introduced on the carbon backbone of TTDA (3,6,10-tri(carboxymethyl)-3,6,10-tri(azadodecaneoic acid) to increase lipophilicity to the Gd(III) complex upon cleavage of a legumain-specific peptide substrate (Leg(L)) linked to the benzyl group. Legumain-mediated cleavage of the peptide substrate thus facilitates better wrapping of the Gd(III) ion and increases the water exchange rate ($k_{ex}$). The CyTE777-Leg(L)-CyTE807 was created by conjugating two NIR fluorochromes (CyTE777 and CyTE807) to Leg(L). In close proximity, emission from CyTE777 is expected to transfer to CyTE807, thus quench CyTE777 signals. We postulated that enzymatic removal of the peptide substrate of [Gd-NBCB-TTDA-Leg(L)], followed by binding with HSA would eventually lead to the formation of macromolecules. On the other hand, enzymatic removal of the peptide substrate of CyTE777-Leg(L)-CyTE807 would increase the distance between these two fluorochromes, and unveil the NIR fluorescent emission from CyTE777 (Fig. 1). The MRI contrast agent and the NIR fluorescent probe were evaluated by in vitro and in vivo MR imaging and optical imaging, respectively. A nude mice model bearing subcutaneous tumor xenografts of CT-26 (legumain $^+$) tumor was used for both MR and optical imaging studies.

2. Experimental

2.1. Materials and methods

Ninyhdrin and palladium/charcoal (10% Pd) were purchased from Merck (Die- tikon, Switzerland), O-(7-Aza-1H-benzotriazole-1-yl)-N,N,N′,N′-tetramethyluronium (HATU), N-methylmorpholine, trifluoroacetic acid (TFA), N-ethyldiisopropylamylamine, magnesium sulfate anhydrous, N-methyl morpholine, and N,N′-dicyclohex- ylcarbodiimide (DCC) were purchased from Alfa Aesar (Ward Hill, US). Tritylaldehyde (TIS), acetic anhydride, and hydrazine monohydrate were purchased from Acros (Fair Lawn, US). Borane tetrahydrofuran complex solution in THF (BH$_3$·THF), cyclobutane-1,1-di-carboxamide, succinic anhydride, thionyl chloride (SOCl$_2$), 3-mercaptobenzoic acid, and Dubeczko’s minimal essential medium were purchased from Sigma–Aldrich (St. Louis, US). Fmoc-Ala, Fmoc-(L)-Asn(Trt), Fmoc-Lys(Boc), Fmoc-Lys(ω-De), Fmoc-(D)-Asn(Trt), Fmoc-Leu, rink amide resin (200–400 meshes), N-hydroxybenzotriazole (HOBT), and benzotriazole-1-yl-oxy-tris-pyrroldino-phosphoniumhexafluorophosphate (PyBOP) were purchased from Nova- biochem (Nottingham, UK). N-methyl-2-pyrrolidinone (NMP) was purchased from biochem (Nottingham, UK). N-methylmorpholine, triethylsilane, benzotriazole-1-yl-oxy-tris-pyrroldino-phosphoniumhexafluorophosphate (PyBOP) were purchased from Nova- biochem (Nottingham, UK). N-methyl-2-pyrrolidinone (NMP) was purchased from Mallinckrodt Baker (Phillipsburg, US). All other chemicals and reagents for the synthesis and biological studies were of high quality and procured commercially from the reputed suppliers. The peptide synthesis was performed on PS-3 (Ridgefield, NJ, US). The 1H NMR and 13C NMR spectra of the compounds were recorded in deuterated water ($D_2$O) and deuterated dimethylsulfoxide ($DMSO$-$d_6$) at room temperature using tetramethylsilane as an external standard on a Unity-300 NMR spectrometer (Varian, CA, US). LC-MS analyses were performed with Micromass ZQ-4000 and Q-Tof (Waters, MA, US). HPLC analysis was performed on AKTA basic 10 system (Amersham-Pharmacia, NJ, US) equipped with an UV-900 detector, Frac-920 fraction collector and RP-C18 column (5 µm, 4.6 × 250 mm) (Supelco, PA, US), eluted at a flow rate of 1 mL/min with a solvent system consisting of 0.1% TFA/H$_2$O (solvent A) and TFA/CH$_3$CN (solvent B). UV/Vis and fluorescence spectra were measured with U-3010 UV/Vis spectrophotometer (Hitachi, Tokyo, Japan) and F-9000 fluorescence spectrophotometer (Hitachi, Tokyo, Japan) at room temperature, respectively. The relaxation time ($T_1$) measurements were performed using NMR-120 Minispec relaxometer (Bruker, Ettlingen, Germany) operating at 20 MHz and 37.0 ± 0.1 °C.

Fig. 1. Systematic representation of (A) MRI contrast agent ([Gd-NBCB-TTDA-Leg(L)]) and (B) NIR fluorescent probe (CyTE777-Leg(L)-CyTE807) for legumain detection.
In vitro and in vivo MR imaging was recorded on a 7.0-T Biospec MR scanner (Bruker, Ettlingen, Germany) with a volume coil used as a radio frequency transmitter and receiver. In vitro and in vivo optical images were acquired using IVIS Spectrum System (Caliper, MA, US).

2.2. Synthesis

Syntheses of peptide substrate (Fmoc-Leu-(L)-Asn(Trt)-Ala-Ala-Lys(Boc)-Lys(Boc)-Lys(Boc)-Lys(ivDde), Leg(L)) and Fmoc-Leu-(D)-Asn(Trt)-Ala-Ala-Lys(Boc)-Lys(Boc)-Lys(Boc)-Lys(ivDde), Leg(D))

The solid-phase peptide assembled on PS-3 peptide synthesizer was synthesized using rink amide resin (0.63 mmol/g) by Fmoc chemistry. The side chain protecting groups of trifunctional amino acids were trifluoroacetic acid labile. Legumain peptide substrate (Fmoc-Leu-(L)-Asn(Trt)-Ala-Ala-Lys(Boc)-Lys(Boc)-Lys(Boc)-Lys(ivDde), Leg(L)) was synthesized on a 0.16 mmol scale using a 4-fold molar excess of Fmoc-protected amino acids (0.62 mmol), which were activated by 4-fold excess of PyBOP in the presence of N-methylmorpholine (20% v/v) in DMF. N-Fmoc protecting groups were removed by treating the resin-attached peptide with piperidine (20% v/v) in DMF. The legumain functionalized resin (0.25 g, 0.16 mmol) was deprotected with the piperidine solution and washed in DMF as described above. The collected fractions yielded legumain peptide substrate as a green powder (253 mg, 85.8%). ESI-MS m/z calcd for C41H51N2O8S3: 899.14, found: 899.61 [M+H]+. The control legumain peptide substrate (Fmoc-Leu-(D)-Asn(Trt)-Ala-Ala-Lys(Boc)-Lys(Boc)-Lys(Boc)-Lys(ivDde), Leg(D)) was synthesized by following the steps as mentioned for Leg(L) by utilizing D-form asparagine as reaction substrate. The collected fractions yielded legumain peptide substrate as a green powder (241 mg, 81.7%). ESI-MS m/z calcd for C41H51N2O8S3: 899.14, found: 899.83 [M+H]+.

The details of the synthesis of compounds 1 to 6, 11, and 12 are reported in the Supporting Information (Schemes S1 and S2), and compounds 7 to 10, and 13 to 14 are depicted in Schemes 1 and 2. The procedures are described as below.

2.2.1. Syntheses of NBCB-TTDA-Leg(L) (7) and NBCB-TTDA-Leg(D) (8)

In order to expose the N-terminal of peptide, the resin (0.5 g, 0.20 mmol) was soaked in NMP (2 mL) for 1 h. At the same time, HATU (120 mg, 0.32 mmol)/DMF 6 + L(Trt)N(R)AAK(Boc)K(Boc)K(Boc)K(Boc)O

\[ O\]

95% TFA

2.5% TIS

2.5% H2O

HN

R = L form, NBCB-TTDA-Leg(L), 7

R = D form, NBCB-TTDA-Leg(D), 8

\[ \text{Scheme 1. Synthetic scheme of [Gd-NBCB-TTDA-Leg(L)] and control contrast agent ([Gd-NBCB-TTDA-Leg(D)]).} \]
(2.5 mL) was added to a solution of NBCB-COOH-Sest (6: 0.32 g, 0.34 mmol) in NMP (3 mL) and shaken vigorously for 15 min. DIEA/NMP (1 mL, 2 mL) was then added to the above mixture for 15 s to activate the ligand. The ligand solution was added to the resin and the resulting mixture was shaken vigorously for 5 s. After the reaction was completed, the cleave reagent (10 mL); TFA: deionized water: TIS = 95: 2.5: 2.5 (v/v)) and the resulting mixture was vigorously stirred for 2 h, washed in CHCl3 and methanol and filtered. After filtration, TEA was added to the mixture to neutralize remnant TFA and then the solvent was vaporized under reduced pressure. To the residue, cold diethyl ether was added and mixture was centrifuged (1500 rpm) for 5 min to precipitate. The same step was repeated for 3–5 times and the white precipitate obtained was collected and lyophilized using deionized distilled water. The freeze-dried powder was calculated: 1685.98, found: 1686.66 [M+CONH2] and mixture was centrifuged (1500 rpm) for 5 min to precipitate. The same step was repeated 5 times and the white precipitate obtained was collected and lyophilized using deionized distilled water. The freeze-dried powder was calculated: 1685.98, found: 1685.75 [M+H]. The freeze-dried powder was then added to the above solutions and stirred at 25 °C for 72 h. The completion of complex formation was confirmed by xylene orange test. The solution was filtered and lyophilized to give the white powders complex 9. The purity of [Gd-NBBC-TTDA-Leg-L] was determined by HPLC, and the identity was confirmed by mass spectrometry. ESI-MS: m/z calculated: 1533.77, found: 1533.69 [M+H]+. The concentration of complexes was measured by comparing the absorption of the complexes with a known concentration of standards.

2.2. Preparation of [Gd-NBBC-TTDA-Leg-D] (9) and [Gd-NBBC-TTDA-Leg-L] (10)

The ligand (NBCB-TTDA-Leg(L)) was dissolved in deionized water (5 mL) and the pH was adjusted to 5.3–6.5 using sodium hydroxide. GdCl3(aq) (510.7 μL, 94.6 mmol) was then added to the above solutions and stirred at 25 °C for 72 h. The completion of complex formation was confirmed by xylene orange test. The solution was filtered and lyophilized to give the white powders complex 9. The purity of [Gd-NBBC-TTDA-Leg-L] was determined by HPLC, and the identity was confirmed by mass spectrometry. ESI-MS: m/z calculated: 1685.98, found: 1685.75 [M+H]. The purity of [Gd-NBBC-TTDA-Leg-D] was determined by HPLC (Fig. S1) and the identity was confirmed by mass spectrometry. ESI-MS: m/z calculated: 1533.77, found: 1534.22 [M+H]+.

2.2.3. Synthesis of Cy777-Leg(L)-Cy787 (13) and Cy777-Leg(D)-Cy787 (14)

In a separated vial, Cy777 (446 mg, 0.57 mmol) and HOBt (77.2 mg, 0.57 mmol) were dissolved in DMF (5 mL) and cooled to 0 °C. DCC (116.9 mg, 0.57 mmol) was added and dissolved by stirring. The solution was then warmed to room temperature and allowed to stand for 24 h after which it was added to the legumain peptide substrate (Leg(L)). The side chain protection group (ivDde) on (L)-Leg was removed by 2% hydrazine in DMF. In a separated vial, Cy787 (453 mg, 0.57 mmol) and HOBt (77.2 mg, 0.57 mmol) were dissolved in DMF (5 mL) and cooled to 0 °C. To this, DCC (116.9 mg, 0.57 mmol) was added and dissolved by gentle stirring. The solution was warmed to the room temperature and allowed to stand for 24 h after which it was added to the solution. When the reaction was completed, the peptide solution was removed. The resin was washed in DMF and methanol, and dried under vacuum. The cleave reagent (10 mL): TFA: deionized water: TIS = 95: 2.5: 2.5 (v/v)) and the resin was added, and 50 mL of distilled H2O was bubbled through the mixture for 2 h. After removing resin, Cy777-Leg-L-Cy787 (13) was precipitated in ice-cold diethyl ether and centrifuged (1500 rpm) for 5 min. Cy777-Leg-L-Cy787 was concentrated, dissolved in H2O, and lyophilized to yield white powder compound 13 (229.6 mg, 42.3%). MOLDI-TOF-MS: m/z calculated: 2441.17, found: 2440.92 [M+H]+.

2.3. Luminescent method for establishing solution hydration state

Luminescence lifetime data was obtained for the Eu(III) complex to determine the number of inner-sphere water molecules in the aqueous solution. The luminescence lifetime (τ) has been determined in both H2O and D2O. The complex containing the number of inner-sphere water was calculated by equations (1) and (2) [28,36].

\[
q = A \left[1/\tau_{H2O} - 1/\tau_{D2O}\right] \quad A = 1.05
\]

(1)

\[
q = \left(1/\tau_{H2O} - 1/\tau_{D2O}\right) \times 1.2
\]

(2)

where q is the number of water molecules bound to metal ions, τH2O is luminescence half-life in water solution and τD2O is the luminescence half-life in deuterium oxide solution.

2.4. Relativity (r1) measurement

To study the effect of legumain on the longitudinal relaxation time (T1) of [Gd-NBBC-TTDA-Leg-L] and the control contrast agent ([Gd-NBBC-TTDA-Leg-D]), T1 values were measured in the presence and absence of legumain and HSA, respectively. All the T1 values were measured using a 20 MHz relaxometer operating at 370 ± 0.1 °C. Before each measurement, the relaxometer was tuned and calibrated. The T1 values were plotted against the concentration of agents, to get six data points, respectively. Furthermore, the values of r1 were determined from the slope of six data points generated by an inversion-recovery pulse sequence.

2.5. Cell lines and animal model

Legumain-expressing 3T3 (legumain+) cell line was a 3T3 cell line transfected with legumain cDNA. CT-26 (legumain−) murine colon carcinoma cells, 3T3, and legumain-expressing 3T3 (legumain+) cell lines were cultured in Dulbecco’s minimal essential medium supplemented with 10% bovine serum, penicillin (100 μg/mL) and streptomycin (100 μg/mL) with 5% CO2 at 37 °C. Nude mice (5 weeks old, male) were purchased from the National Laboratory Animal Center (Taipei, Taiwan). Animal experiments were performed in accordance with the institutional guidelines. CT-26 (legumain+) cells (105 cells) in PBS (100 μL) with equal volume of matrigel were subcutaneously injected into nude mice (n = 4) and used for in vivo studies. Cells were injected into the right lateral thigh of the mice. MR imaging was performed two weeks after tumor implantation, at which time the tumors were measured approximately 500 mm3 in volume.

2.6. Cell cytotoxicity

CT-26 and 3T3 cell lines (105 cells) were seeded to the 96-well plates and incubated for 24 h, respectively. Then, [Gd-NBBC-TTDA-Leg-L], [Gd-NBBC-TTDA-Leg-D], Cy777-Leg-L-Cy787, and Cy777-Leg-L-Cy787 (each in the range
of 0.01–10 μM) were added to the wells. After incubated for 24 h, the supernatant was removed and the cells washed three times in PBS. Cell viability was estimated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) conversion test. MTT (50 μL) solution was added to each well for 2 h, each well was then treated with dimethyl sulfoxide (50 μL) and measured by an ELISA reader at the absorption wavelength set at 570 nm. The data represent the average of sixteen wells. The viability of untreated cells was assumed to be 100%.

2.6.1. In vitro MR imaging study

For the enzymatic cleavage, the MR images of [Gd-NBCB-TTDA-Leg(L)] and control contrast agent ([Gd-NBCB-TTDA-Leg(D)]) were recorded in the presence and absence of legumain and HSA, respectively. All the MR images were obtained by using T1-weighted (TR/TE = 100/10 ms) two-dimensional spin-echo sequence and the contrast enhancement (%) was calculated by the following equation (3)

\[ \text{Enhancement} \% = \frac{\text{SI}_{\text{post}} - \text{SI}_{\text{pre}}}{\text{SI}_{\text{pre}}} \times 100 \] (3)

where \(\text{SI}_{\text{post}}\) is the value of signal intensity of [Gd-NBCB-TTDA-Leg(L)] or control contrast agent ([Gd-NBCB-TTDA-Leg(D)]) with cells and \(\text{SI}_{\text{pre}}\) is the value of signal intensity of [Gd-NBCB-TTDA-Leg(L)] or control contrast agent ([Gd-NBCB-TTDA-Leg(D)]) alone.

2.7. In vitro optical imaging study

CyTE77-Leg(L)-CyTE807 and the control probe (CyTE77-Leg(D)-CyTE807) were prepared with various concentrations (0.1, 0.3, 0.63, 1.25, and 2.50 μM). The cell lysates of legumain-expressing 3T3 (legumain \(^{+}\)) or 3T3 cells (10^6 cells each) were incubated with CyTE77-Leg(L)-CyTE807 and the control probe for 30 min at 37 °C. All samples were scanned at wavelength of excitation 745 nm and emission 820 nm. The contrast enhancement (%) was calculated by equation (3) by considering \(\text{SI}_{\text{post}}\) is the value of signal intensity of CyTE77-Leg(L)-CyTE807 or the control probe (CyTE77-Leg(D)-CyTE807) with cells and \(\text{SI}_{\text{pre}}\) is the value of signal intensity of CyTE77-Leg(L)-CyTE807 or the control probe (CyTE77-Leg(D)-CyTE807) alone.

2.8. In vivo MR imaging study

Nude mice bearing CT-26 (legumain \(^+\)) tumors were studied by MR imaging when the subcutaneous tumor xenografts reached approximately 500 mm^3. A solution of [Gd-NBCB-TTDA-Leg(L)] (0.1 mmol/kg) was injected via the tail veins. The MR imaging of pentobarbital-anesthetized mice was performed every 10 min for 1 h, using 7.0-T Biospec MR scanner with a volume coil used as radio frequency transmitter and receiver. All animals were scanned using a T1-weighted fast spin-echo sequence (TR/TE/flip angle = 400/15/10°) for imaging and the corresponding contrast enhancement (%) was calculated by equation (3) by considering \(\text{SI}_{\text{post}}\) is the value of signal intensity for [Gd-NBCB-TTDA-Leg(L)] or the control contrast agent [Gd-NBCB-TTDA-Leg(D)] targeted on tumor cells, and \(\text{SI}_{\text{pre}}\) is the value of signal intensity before [Gd-NBCB-TTDA-Leg(L)] or the control contrast agent [Gd-NBCB-TTDA-Leg(D)] injection.

2.9. In vivo optical imaging study

For the optical imaging experiments, tumor-bearing nude mice were injected via tail veins with CyTE77-Leg(L)-CyTE807 and the control probe (CyTE77-Leg(D)-CyTE807) targeted on tumor cells, and SIpre is the value of signal intensity of CyTE77-Leg(L)-CyTE807 or the control probe (CyTE77-Leg(D)-CyTE807) alone.

**Table 2**

<table>
<thead>
<tr>
<th>Compounds</th>
<th>pH</th>
<th>Reliability ((\text{r}_1))/mM^{-1}s^{-1}</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Gd-NBCB-TTDA-Leg(L)]</td>
<td>7.4 ± 0.1</td>
<td>4.94 ± 0.03</td>
</tr>
<tr>
<td>[Gd-NBCB-TTDA-Leg(D)]</td>
<td>7.4 ± 0.1</td>
<td>4.94 ± 0.03</td>
</tr>
<tr>
<td>[Gd-NBCB-TTDA]2−</td>
<td>7.4 ± 0.1</td>
<td>4.28 ± 0.02</td>
</tr>
<tr>
<td>[Gd(TTDA)]2−</td>
<td>7.4 ± 0.1</td>
<td>3.85 ± 0.03</td>
</tr>
</tbody>
</table>

\(^{a}\) Data were obtained from Ref. [38].
Fig. 3. Cell cytotoxicity of \([\text{Gd-NBCB-TTDA-Leg(L)}]\) (A) and \([\text{Gd-NBCB-TTDA-Leg(D)}]\) (B), as function of different concentrations (62.5–1000 \(\mu\text{M}\)) in MTT assay. Cell cytotoxicity of \([\text{CyTE777-Leg(L)-CyTE807 (C)}]\) and \([\text{CyTE777-Leg(D)-CyTE807 (D)}]\) as function of different concentrations (0.01–10 \(\mu\text{M}\)) in MTT assay.

Fig. 4. (A) In vitro \(T_1\)-weighted MR images of legumain-expressing 3T3 (legumain\(^{+}\)) and 3T3 cells treated with 0.25 \(\text{mM}\) of \([\text{Gd-NBCB-TTDA-Leg(L)}]\) and \([\text{Gd-NBCB-TTDA-Leg(D)}]\) in the presence and absence of HSA; (B) color-map of MR imaging.
3.4. Relaxivity (r1) study

The relaxivity (r1) values of [Gd-NBCB-TTDA-Leg(L)], [Gd-NBCB-TTDA-Leg(D)], [Gd(NBCB-TTDA)]2⁺, and [Gd(TTDA)]2⁺ at 370 ± 0.1°C are shown in Table 2. The relaxivity values obtained for [Gd-NBCB-TTDA-Leg(L)], [Gd-NBCB-TTDA-Leg(D)], [Gd(NBCB-TTDA)]2⁺, and [Gd(TTDA)]2⁺ fall within the usual range that corresponds to single hydration (Table 1). The relaxivity of [Gd-NBCB-TTDA-Leg(L)] is similar to that of [Gd-NBCB-TTDA-Leg(D)], and slightly higher than those of [Gd(NBCB-TTDA)]2⁺ and [Gd(TTDA)]2⁺ likely due to conjugation of the legumain-specific peptide substrate or control peptide thus reduces the tumbling rate and enhances relaxivity [28,38].

3.5. Fluorescent study of legumain-induced peptide cleavage of CyTE777-Leg(L)-CyTE807

The NIR fluorescent probe (CyTE777-Leg(L)-CyTE807) was created by conjugating two NIR fluorochromes (CyTE777 and CyTE807) to Leg(L). The emission maxima of CyTE777-Leg(L)-CyTE807, CyTE777, and CyTE807 were 840, 820, and 840 nm, respectively (Fig. 2 and 3). The fluorescent signals of CyTE777 molarity was completely quenched by CyTE807 resulting from a combination of static quenching and FRET mechanisms [39]. To examine the extent of peptide cleavage by legumain, CyTE777-Leg(L)-CyTE807 was incubated with legumain-transduced 3T3 cell lysate for 0.5 h and then its emission recorded. As shown in Fig. 2, cleavage of the Leg(L) substrate occurred as a consequence of the specific substrate recognition by legumain-induced hydrolysis of asparaginyl bond (Leu–Asn bond) on the legumain peptide substrate. This cleavage induced a slight wavelength shift from 840 nm to 820 nm as compared with the emission from probes without incubation in 3T3 (Leg(L)) cell lysate. These results indicated that CyTE777-Leg(L)-CyTE807 could be recognized by legumain. Two fluorochromes (CyTE777 and CyTE807) connected by a peptide is expected to quench fluorescent emission by one of the dyes. Cleavage of peptide substrate increased the distance between these two fluorochromes, and revealed the fluorescence emission previously quenched. These results demonstrate that CyTE777-Leg(L)-CyTE807 is recognized specifically on the cleavage site by legumain.

3.6. Cell cytotoxicity

Cytotoxicity is an important parameter for applying the imaging agents in biomedical studies. We used MTT assay to evaluate cytotoxicity of [Gd-NBCB-TTDA-Leg(L)], [Gd-NBCB-TTDA-Leg(D)], CyTE777-Leg(L)-CyTE807, and CyTE777-Leg(D)-CyTE807 to CT-26 (Leg(L)) and 3T3 cell lines. As shown in Fig. 3, [Gd-NBCB-TTDA-Leg(L)], [Gd-NBCB-TTDA-Leg(D)], CyTE777-Leg(L)-CyTE807 and CyTE777-Leg(D)-CyTE807 displayed low cytotoxicity even at high concentrations of the probes.
Fig. 6. In vivo $T_1$-weighted MR images of mice bearing CT-26 (legumain$^+$) xenografts pre- and post-injection of [Gd-NBCB-TTDA-Leg(L)] (0.1 mmol/kg) (A). MR imaging was performed on 7.0-T Biospec MR scanner by fast spin echo pulse sequence (TR/TE = 400/15). (B) Color-map of (A).

Fig. 7. In vivo $T_1$-weighted MR images of mice bearing CT-26 (legumain$^+$) xenografts pre- and post-injection of [Gd-NBCB-TTDA-Leg(D)] (0.1 mmol/kg) (A). MR imaging was performed on 7.0-T Biospec MR scanner by fast spin echo pulse sequence (TR/TE = 400/15). (B) Color-map of (A).
[Gd-NBCB-TTDA-Leg(L)] (Fig. 4). [Gd-NBCB-TTDA-Leg(L)] showed marked contrast enhancement compared to the control contrast agent ([Gd-NBCB-TTDA-Leg(D)]) (73.5 ± 2.4% vs. 28.4 ± 1.1%, in presence of legumain activity and HSA) [38], likely due to D-form asparagine in the peptide sequence of the control probe renders the peptide resistant to hydrolysis by legumain. These in vitro MR imaging results indicate that legumain significantly and specifically increased contrast enhancement of [Gd-NBCB-TTDA-Leg(L)] but not of the control contrast agent [Gd-NBCB-TTDA-Leg(D)].

3.8. In vitro optical imaging

In vitro optical imaging studies were performed with graded concentrations of CyTE777-Leg(L)-CyTE807 and control probe CyTE777-Leg(D)-CyTE807 with the legumain-expressing 3T3 (legumain⁺) or 3T3 cell lysate. As shown in Fig. 5, signal intensity of CyTE777-Leg(L)-CyTE807 was increased by incubation with legumain-expressing 3T3 (legumain⁺) cell lysate. In the absence of legumain, signal intensity was slightly increased maybe due to non-specific cleavage to the probe. Only marginal increase in the signal intensity of control probe (CyTE777-Leg(D)-CyTE807) was noted when present at high concentrations. These results indicate that CyTE777-Leg(L)-CyTE807 was specifically cleaved by legumain such that self-quench between CyTE777 and CyTE807 was relieved.

3.9. In vivo MR imaging

In vivo MR imaging was carried out for [Gd-NBCB-TTDA-Leg(L)] and the control contrast agent ([Gd-NBCB-TTDA-Leg(D)]). Images were acquired at pre-injection and various time points (1 min, 0.5 h, 1 h, 2 h, 3 h, and 24 h) after injection of contrast agents to nude mice bearing CT26 (legumain⁺) tumors. The MR images of [Gd-NBCB-TTDA-Leg(L)] and [Gd-NBCB-TTDA-Leg(D)] after intravenous injection were shown in Figs. 6 and 7. The contrast enhancements (%) at CT26 tumors after [Gd-NBCB-TTDA-Leg(L)] injection reached 4.5%, 39.9%, 146.1%, 254.2%, 103.5%, and 3.9%, respectively. In contrast, only slight enhancements (3.9% at 1 h post-injection, and 4.6% at 2 h post-injection) were observed for the control contrast agent [Gd-NBCB-TTDA-Leg(D)]. The relative contrast enhancement were 37.5 (146.1% versus 3.9%, 1 h post-injection) and 55.3 (254.2% versus 4.6%, 2 h post-injection) fold higher with [Gd-NBCB-TTDA-Leg(L)], compared to the control contrast agent. Thus, [Gd-NBCB-TTDA-Leg(L)] maybe an useful contrast agent for in vivo MR imaging of legumain-expressing tumors.

3.10. In vivo optical imaging

To investigate the usefulness of CyTE777-Leg(L)-CyTE807, in vivo imaging of mice bearing CT-26 (legumain⁺) tumors was attempted. CyTE777-Leg(L)-CyTE807 or CyTE777-Leg(D)-CyTE807 were intravenously injected into the tumor-bearing nude mice via tail veins. The fluorescent signals were recorded in mice at various time points (0.5 h, 1 h, 4 h, and 24 h) after injection. As demonstrated in Fig. 8, high fluorescent intensities were observed in the tumors for the mice treated with CyTE777-Leg(L)-CyTE807 (5.23 × 10⁹ photons/min at 0.5 h and 3.34 × 10⁸ photons/min at 24 h post-injection). Furthermore, fluorescent signal persisted in CT-26 (legumain⁺) tumor over 24 h. On the contrary, minimal

Fig. 8. In vivo NIR fluorescence images of CyTE777-Leg(L)-CyTE807 and the control probe (CyTE777-Leg(D)-CyTE807). Mice bearing CT-26 (legumain⁺) tumor xenograft were injected CyTE777-Leg(L)-CyTE807 (2 μmol/kg) (A) and CyTE777-Leg(D)-CyTE807 (2 μmol/kg) (B). Optical images were acquired pre-injection, 0.5 h, 1 h, 4 h, and 24 h post injection. (excitation: 745 nm; emission: 820 nm).
fluorescent signal was found in the tumors for the mice treated with CyTE777-Leg(D)-CyTE807 (4.98 \times 10^9 photons/min at 0.5 h and 0.22 \times 10^9 photons/min at 24 h, Fig. 8B). The relative fluorescent enhancements were 1.1 fold higher at 0.5 h and 15.2 fold higher at 24 h post-injection with CyTE777-Leg(L)-CyTE807 injection. These results indicate that CyTE777-Leg(L)-CyTE807 is a specific optical imaging probe for legumain-expressing tumors.

3.11. Biodistribution study

The biodistributions of CyTE777-Leg(L)-CyTE807 and control probe (CyTE777-Leg(D)-CyTE807) were examined. CT-26 (legumain⁺) tumor and other organs were excised and subjected to optical imaging at 24 h post-injection of CyTE777-Leg(L)-CyTE807 or CyTE777-Leg(D)-CyTE807. As shown in Fig. 9, marked fluorescent intensities of CyTE777-Leg(L)-CyTE807 treated mice were noted in CT-26 (legumain⁺) tumors, livers, and kidneys (5.89 \times 10^8 photons/min, 1.28 \times 10^10 photons/min, and 1.59 \times 10^9 photons/min, respectively) whereas moderate intensities were detected in skin, pancreata, bones, stomachs, and spleens. Signal percentage per dose gram (% ID/g) for CT-26 (legumain⁺) tumors, livers, and kidneys were 18.3%, 21.2%, and 7.2%, respectively. On the other hand, fluorescent signals of CyTE777-Leg(D)-CyTE807 treated mice was observed in CT-26 (legumain⁺) tumors and livers (9.99 \times 10^8 photons/min and 1.62 \times 10^9 photons/min, Fig. 10B). The corresponding % ID/g values for tumors and livers were 1.6% and 26.1% (Fig. 10C). These results clearly demonstrate that CyTE777-Leg(L)-CyTE807 can effectively and specifically accumulate in tumors that over-expresses legumain.

4. Conclusion

In summary, a MRI contrast agent ([Gd-NBCB-TTDA-Leg(L)]) and a NIR fluorescent probe (CyTE777-Leg(L)-CyTE807) were successfully developed. Legumain-mediated cleavage of the substrate peptide increases contrast enhancements or fluorescent intensity of the respective probes. Our data indicate that the contrast agent...
and the optical probe can specifically and efficiently target legumain-expressing cancers \textit{in vivo}. Potentially, this strategy can be used for \textit{in vivo} imaging of other proteases by changing the substrate peptides in the constructs. This unique development of efficient MRI contrast agent and optical probe may be useful for detection of \textit{in vivo} legumain expression in biomedical studies.

**Acknowledgments**

We are grateful to the National Science Council of Taiwan for financial support under contracts no. NSC 101–2627–M-009-006. This research was particularly supported by “Aim for the Top University Plan” of the National Chiao Tung University and Ministry of Education.

**Appendix A. Supplementary data**

Supplementary data related to this article can be found online at http://dx.doi.org/10.1016/j.biomaterials.2013.09.100.

**References**


**Fig. 10.** \textit{In vivo} fluorescent images of dissected organs of the mouse bearing CT-26 (legumain$^+$) tumors, sacrificed 24 h after intravenous injection of CyTE777-Leg(D)-CyTE807 (20 nmol) (excitation: 745 nm; emission: 820 nm). (A) White light image (1) blood, (2) heart, (3) kidney, (4) skin, (5) muscle, (6) brain, (7) pancreas, (8) bone, (9) liver, (10) stomach, (11) lung, (12) spleen, (13) CT-26 (legumain$^+$) tumor); (B) near-infrared fluorescence images; (C) quantitative fluorescence intensities of dissected organs of the mouse.
Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary

Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen XJ. Small-animal PET of tumors with


superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent

Cheng Z, Thorak DL, Tsourkas A. Gadolinium-conjugated dendrimer nano-
clusters as a tumor-targeted T1 magnetic resonance imaging contrast agent.

Xen H, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of

infrared fluorescent type II quantum dots for sentinel lymph node mapping.

Colak SB, van der Mark MB, Hooft GW, Hoogengaard JH, van der Linden EW,
Kuijpers FA. Clinical optical tomography and NIR spectroscopy for breast

Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat

Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol 2001;19:
316-7.

Tung CH. Fluorescent peptide probes for in vivo diagnostic imaging. Bio-
polymers 2004;76:391.

Rao J, Dragulescu-Andrasi A, Yao H. Fluorescence imaging in vivo: recent

Artiomov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular

Artiomov D, Mori N, Okolie B, Bhujwalla ZM. MR molecular imaging of the
Her-2/neu receptor in breast cancer cells using targeted iron oxide nano-

Wrezusch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary
brain tumors: current concepts and review of the literature. Neuro-Oncology

Parsons SI, Watson SA, Steele RJ. Phase I/II trial of batimastat, a matrix met-
alloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases:

A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel
matrix metalloproteinase inhibitor, in patients with advanced and refractory

Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase
inhibitor B894 in patients with malignant ascites. Clin Cancer Res 1998;4:
1899-902.

Wang YM, Lee CH, Liu GC, Sheu RS. Synthesis and complexation of Cd1½,
Ca2+, Cu2+ and Zn2+ by 3, 6, 10-tri (carboxymethyl)-3, 6, 10-triazadodecanedioic

Lee J, Bogyo M. A bright approach to the immunoproteasome: Development of

van Eijk M, Johannes C, van Noorden F, de Groot C. Proteinases and their

Chen JM, Fortunato M, Stevens RA, Barrett AJ. Inhibition of distant caspase

Shirahama-Noda K, Yamamoto A, Sugihara K, Hashimoto N, Asano M,
Nishimura M, Haraz-Nishimura I. Biosynthetic processing of cathepsins and
lysosomal degradation are abolished in asparaginyl endopeptidase-deficient

Saranadeses C, Covelo G, Diaz-Julien C, Freire M. Prothymosin α is processed
to thymosin α1 and thymosin α1L by a lysosomal asparaginyl endopeptidase.

Morita Y, Araki H, Sugimoto T, Takeuchi K, Yamane T, Maeda T, et al. Legu-
main/asparaginyl endopeptidase controls extracellular matrix remodeling
through the degradation of fibronectin in mouse renal proximal tubular cells.

imaging for gastric releasing peptide receptor of prostate cancer tumor using

Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free
targeted amino groups in the solid-phase synthesis of peptides. Anal Biochem

Hilderbrand SA, Kelly KA, Weissleder R, Tung CH. Monofunctional near-
infrared fluorochromes for imaging applications. Bioconjug Chem 2005;16:
1275-81.

Chang YH, Chen CY, Singh G, Chen HY, Liu GC, Goan YC, et al. Synthesis and
physicochemical characterization of carbon backbone modified [Gd

Johansson MK, Cook RM. Intramolecular dimers: a new design strategy for